ACIU - ACイミュ―ン (AC Immune SA)

ACIUのニュース

   AC Immune (ACIU) Moves to Buy: Rationale Behind the Upgrade  2020/02/10 17:00:06 Zacks Investment Research
AC Immune (ACIU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   AC Immune (ACIU) Expected to Beat Earnings Estimates: Should You Buy?  2019/11/05 15:33:45 Zacks Investment Research
AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   AC Immune to Earn Milestone From Lilly for Alzheimer's Drug  2019/09/23 17:22:00 Zacks Investment Research
AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.
   Analysts Estimate AC Immune (ACIU) to Report a Decline in Earnings: What to Look Out for  2019/08/07 14:30:34 Zacks Investment Research
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   AC Immune Initiates Phase I Study for Alzheimer's Disease  2019/07/18 14:26:00 Zacks Investment Research
AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.
   AC Immune (ACIU) Moves to Buy: Rationale Behind the Upgrade  2020/02/10 17:00:06 Zacks Investment Research
AC Immune (ACIU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   AC Immune (ACIU) Expected to Beat Earnings Estimates: Should You Buy?  2019/11/05 15:33:45 Zacks Investment Research
AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   AC Immune to Earn Milestone From Lilly for Alzheimer's Drug  2019/09/23 17:22:00 Zacks Investment Research
AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.
   Analysts Estimate AC Immune (ACIU) to Report a Decline in Earnings: What to Look Out for  2019/08/07 14:30:34 Zacks Investment Research
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   AC Immune Initiates Phase I Study for Alzheimer's Disease  2019/07/18 14:26:00 Zacks Investment Research
AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.
   AC Immune (ACIU) Expected to Beat Earnings Estimates: Should You Buy?  2019/11/05 15:33:45 Zacks Investment Research
AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   AC Immune to Earn Milestone From Lilly for Alzheimer's Drug  2019/09/23 17:22:00 Zacks Investment Research
AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.
   Analysts Estimate AC Immune (ACIU) to Report a Decline in Earnings: What to Look Out for  2019/08/07 14:30:34 Zacks Investment Research
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   AC Immune Initiates Phase I Study for Alzheimer's Disease  2019/07/18 14:26:00 Zacks Investment Research
AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.
   AC Immune (ACIU) Lags Q1 Earnings and Revenue Estimates  2019/05/15 12:35:02 Zacks Investment Research
AC Immune (ACIU) delivered earnings and revenue surprises of -36.09% and -29.52%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

calendar